Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Vulvovaginal Candidiasis Therapeutics Report 2016: Pipeline Review of 6 Companies & 10 Drug Profiles - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Vulvovaginal Candidiasis - Pipeline Review, H2 2016" report to their offering.

Vulvovaginal Candidiasis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. Our latest report Vulvovaginal Candidiasis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Vulvovaginal Candidiasis refers to a disorder characterized by signs and symptoms of vulvovaginal inflammation in the presence of Candida species. Symptoms of vulvovaginal candidiasis include itching, soreness and/or burning discomfort in the vagina and vulva, heavy white curd-like vaginal discharge, bright red rash affecting inner and outer parts of the vulva, sometimes spreading widely in the groin to include pubic areas, inguinal areas and thighs. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Vulvovaginal Candidiasis Overview
  3. Therapeutics Development
  4. Pipeline Products for Vulvovaginal Candidiasis - Overview
  5. Pipeline Products for Vulvovaginal Candidiasis - Comparative Analysis
  6. Vulvovaginal Candidiasis - Therapeutics under Development by Companies
  7. Vulvovaginal Candidiasis - Therapeutics under Investigation by Universities/Institutes
  8. Vulvovaginal Candidiasis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Vulvovaginal Candidiasis - Products under Development by Companies
  13. Vulvovaginal Candidiasis - Products under Investigation by Universities/Institutes
  14. Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development
  • Cidara Therapeutics, Inc.
  • Grupo Ferrer Internacional, S.A.
  • NovaDigm Therapeutics, Inc.
  • Scynexis, Inc.
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/pg2v24/vulvovaginal

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006385/en/

Business Wire
www.businesswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.